SAN FRANCISCO – Despite tremendous progress in the field of immunotherapy, leading immunologist Jeff Bluestone told an audience at the University of California, San Francisco Tuesday that significant questions remain around how to best navigate the field's future. Bluestone, a professor at UCSF and head of the Parker Institute for Cancer Immunotherapy, said that addressing combinations, understanding immune-related adverse events and autoimmunity will be key in advancing understanding of how to employ what he called an "explosion of new drugs."